Question explored with the scientific record
Did people in Singapore die from the covid vaccine
The short answer: the evidence you retrieved does not contain a single death report from Singapore, nor any Singapore-specific mortality data.
The retrieved studies are all about different topics. One is about a skin rash called "COVID Vaccine Arm" in US and European patients [1]. Another describes a 77-year-old woman in Germany who developed vasculitis after the Pfizer shot and needed permanent dialysis [3]. A third reports a man who got kidney disease after the same vaccine [7]. None of these are from Singapore, and none report a death.
There is a general "post-vaccination syndrome" survey from 2023 that tracked disabling symptoms in 241 people, but again no deaths and no Singapore location [12]. The only study with Asian vaccines is an industry-wide map from 2021 listing platforms and efficacy numbers for Sinovac, Sinopharm, and others — it contains zero safety or mortality data [2].
None of the records cite a death linked to COVID vaccination in Singapore, or anywhere else for that matter. The evidence here simply does not answer the question you asked. That gap is itself worth noting, but it is not a finding of safety or harm.
My call: the retrieved evidence says nothing about deaths from COVID vaccination in Singapore. Confidence: not clear — the gap is total; no study in the retrieval addresses the question.
Sources examined 12
-
Erythema Migrans-like COVID Vaccine Arm: A Literature Review
This literature review investigates the adverse skin reaction known as COVID Vaccine Arm (CVA), characterized by erythema and edema at the vaccination site, and its implications following mRNA COVID-19 vaccinations.
DOI: 10.3390/jcm11030797 -
Asian-Origin Approved COVID-19 Vaccines and Current Status of COVID-19 Vaccination Program in Asia: A Critical Analysis
A critical analysis mapping Asian-origin COVID-19 vaccines and the status of vaccination programs across Asia as of March–May 2021, detailing vaccine platforms, clinical trials, regulatory approvals, demographic coverage, and cost considerations.
DOI: 10.3390/vaccines9060600 -
COVID-19 vaccination-related small vessel vasculitis with multiorgan involvement
This study reports a case of a 77-year-old woman who developed small-vessel vasculitis with multiorgan involvement following the administration of the Pfizer-BioNTech COVID-19 vaccine, highlighting potential autoimmune side effects of COVID-19 vaccinations.
DOI: 10.1007/s00393-022-01159-8 -
The Impact of COVID Vaccination on Symptoms of Long COVID: An International Survey of People with Lived Experience of Long COVID
An international, cross-sectional online survey of 812 adults with long COVID found that a first COVID vaccination was associated with overall symptom improvement in 57.9% of participants and deterioration in 17.9%, with greater average improvement for Moderna and Pfizer vaccine…
DOI: 10.3390/vaccines10050652 -
Who Is Really at Risk for Anaphylaxis Due to COVID-19 Vaccine?
An expert commentary reviews early anaphylaxis reports after Pfizer-BioNTech COVID-19 vaccination and proposes a pragmatic risk-stratification protocol, arguing the MHRA's broad contraindication is overly restrictive.
DOI: 10.3390/vaccines9010038 -
COVID- 19 vaccination reduces new-onset fibromyalgia risk in survivors
This study investigates the protective effect of COVID-19 vaccination on the risk of new-onset fibromyalgia in COVID-19 survivors, finding a significant reduction in risk among vaccinated individuals compared to unvaccinated ones.
DOI: 10.1186/s12916-025-04069-z -
Minimal Change Disease After First Dose of Pfizer-BioNTech COVID-19 Vaccine: A Case Report and Review of Minimal Change Disease Related to COVID-19 Vaccine
This case report documents a 60-year-old man who developed de novo minimal change disease with nephrotic syndrome and acute kidney injury approximately 10 days after a first dose of the Pfizer-BioNTech COVID-19 vaccine, was treated with steroids leading to remission, and is disc…
DOI: 10.1177/20543581211058271 -
The development of China’s vaccine industry in the past decade: the perspective from drug regulatory science
This paper analyzes China’s vaccine industry from a regulatory science perspective over 2011–2020, showing stable overall vaccine production with growth in new and multi‑disease vaccines, ongoing improvements in regulatory standards, and rapid development/approval of vaccines du…
DOI: 10.1080/21645515.2021.2002640 -
Vaccination Coverage in Adult Patients with Inflammatory Bowel Disease: Impact of a Tailored Vaccination Pathway Including COVID-19 and Herpes Zoster in a University Hospital Vaccination Center
A single-center, observational study at the University Hospital Vaccination Center in Messina, Italy, showing that a tailored, multidisciplinary vaccination pathway for adults with inflammatory bowel disease substantially improved vaccination coverage for influenza, pneumococcal…
DOI: 10.3390/vaccines13090961 -
Overview of Knowledge Levels of People Who Are Willing to Vaccinate Against COVID-19 in the COVID-19 Vaccination Program at RSUMM
This study investigates the knowledge levels of individuals willing to vaccinate against COVID-19 at RSUMM, revealing that 87% of respondents demonstrated good knowledge, primarily sourced from social media.
DOI: 10.18502/kme.v3i2.13062 -
Risk of flare or relapse in patients with immune-mediated diseases following SARS-CoV-2 vaccination: a systematic review and meta-analysis
This systematic review and meta-analysis assess the risk of flare or relapse in patients with autoimmune and immune-mediated diseases following SARS-CoV-2 vaccination, finding a minimal overall prevalence of 6.28%, particularly lower with vector-based vaccines.
DOI: 10.1186/s40001-024-01639-4 -
Post-Vaccination Syndrome: A Descriptive Analysis of Reported Symptoms and Patient Experiences After Covid-19 Immunization
This study provides a comprehensive analysis of post-vaccination syndrome (PVS) symptoms and patient experiences following COVID-19 vaccination, highlighting significant health burdens and psychosocial stress among affected individuals.
DOI: 10.1101/2023.11.09.23298266